IX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for IXB 401
IX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for IXB 401
ix生物制药推进了Wafermine的外部授权，并开始进行IXb 401的临床前试验
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间